Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

Por Philipp Schubert, Philipp Schubert, Sandra Rutzner, Sandra Rutzner, Markus Eckstein, Markus Eckstein, Benjamin Frey, Benjamin Frey, Claudia Schweizer, Claudia Schweizer, Marlen Haderlein, Marlen Haderlein, Sebastian Lettmaier, Sebastian Lettmaier, Sabine Semrau, Sabine Semrau, Antoniu-Oreste Gostian, Antoniu-Oreste Gostian, Jian-Guo Zhou, Jian-Guo Zhou, Jian-Guo Zhou, Udo S. Gaipl, Udo S. Gaipl, Rainer Fietkau, Rainer Fietkau, Markus Hecht, Markus Hecht
Publicado em 2020-10-01

Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Por Si-Cong Ma, Xue Bai, Xue-Jun Guo, Li Liu, Lu-Shan Xiao, Yan Lin, Jia-Le Tan, Xiao-Ting Cai, Yu-Xiang Wen, Hu Ma, Q. John Fu, Meng-Xin Leng, Yan-Pei Zhang, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Jian-Guo Zhou, Zhong-Yi Dong
Publicado em 2022-04-01